NPM1 and CD4+/CD56+ hematodermic neoplasm: Further studies have identified overlap in overexpression of CD123 in patients who also have FLT3-ITD- and NPM1-mutated AMLs.370 The first CD123 targeting agent to reach FDA approval in December 2018 for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), another myeloid malignancy with high expression of CD123, was tagraxofusp (SL-401).